Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Immune Response recommended to continue Remune phase III trial

Dec. 12, 1997

Cel-Sci AIDS vaccine effective in mouse model of HIV and immunogenic in humans

Dec. 11, 1997

Antisense AIDS therapy from Novopharm Biotech enters clinical trials

Dec. 10, 1997

HBY-097 + lamivudine highly effective against HIV-1 replication in vitro

Dec. 10, 1997

Adefovir dipivoxil now available in expanded access program

Dec. 9, 1997

PMPA prodrug with favorable biological/pharmaceutical properties

Dec. 5, 1997

Sequence-specific anti-HIV activity reported for the oligodeoxynucleotide SA-1042

Dec. 5, 1997

Actinomycin D: new use in AIDS therapy available for licensing

Dec. 4, 1997

Antiviral thiazolidines and thiazolidinones from INSERM

Dec. 4, 1997

ID Vaccine acquires rights to new AIDS vaccine

Dec. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...